STOK Stock Forecast & Price Target

Stoke Therapeutics Inc is poised for positive growth due to the increasing revenue projections for its lead drug, zorevunersen, which is expected to launch in FY28, with updated estimates boosting its target value to $32. Recent data demonstrating durable improvements in patient outcomes over two years strengthens confidence in the drug's potential for disease modification compared to standard of care antiseizure medications. Furthermore, should the FDA expedite the approval process, there could be additional upside potential for the stock, with estimates rising into the low-$40s, reflecting increased confidence in both the drug's efficacy and market uptake in Dravet syndrome treatment.

Stoke Therapeutics Inc. is currently facing significant financial challenges, as evidenced by its reported net loss of $38.3 million and a net operating loss of $43.1 million in the third quarter of 2025. The company operates within a highly competitive environment for Dravet syndrome therapies, where multiple treatments exist, which could impact the adoption of its lead candidate, zorevunersen, if it fails to deliver the expected long-term benefits. Additionally, Stoke is subject to various industry risks, including potential setbacks from clinical trial results, regulatory hurdles, and the complexities of navigating a price-sensitive market, all of which contribute to a negative outlook on its stock performance.